Jacobs Levy Equity Management, Inc Athira Pharma, Inc. Transaction History

Jacobs Levy Equity Management, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.92 - $2.71 $17,932 - $25,311	9,340 Added 1.88%	506,815 $1.34 Million
Q1 2024 May 15, 2024	BUY	$2.24 - $4.15 $509,102 - $943,203	227,278 Added 84.12%	497,475 $1.36 Million
Q4 2023 Feb 14, 2024	SELL	$1.39 - $2.46 $40,954 - $72,481	-29,464 Reduced 9.83%	270,197 $656,000
Q3 2023 Nov 16, 2023	BUY	$1.9 - $3.16 $187,932 - $312,561	98,912 Added 49.27%	299,661 $605,000
Q2 2023 Aug 14, 2023	SELL	$2.36 - $3.59 $47,976 - $72,981	-20,329 Reduced 9.2%	200,749 $592,000
Q1 2023 May 15, 2023	SELL	$2.26 - $4.22 $71,458 - $133,432	-31,619 Reduced 12.51%	221,078 $552,000
Q4 2022 Feb 14, 2023	BUY	$2.76 - $3.71 $2,103 - $2,827	762 Added 0.3%	252,697 $801,000
Q3 2022 Nov 15, 2022	BUY	$2.93 - $3.96 $738,169 - $997,662	251,935 New	251,935 $748,000

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $23.4M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.